Clinical Trial Update: Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 pharmacokinetic bioequivalence trial comparing Nebcinal inhalation (150 mg/3 mL) via Aeroneb Idehaler to Tobi (tobramycin 300 mg/5 mL) via Pari LC P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Nebcinal
• TOBI (Tobramycin inhalation solution)

Snippet

Sponsor: Erempharma | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: UNKNOWN